



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Klinman et al.

Application No. 10/523,273

Filed: January 31, 2005

Confirmation No. 2295

For: METHOD OF TREATING
INFLAMMATORY ARTHROPATHIES
WITH SUPPRESSORS OF CPG
OLIGONUCLEOTIDES

Examiner: Michelle S. Horning

Art Unit: 1648

Attorney Reference No. 4239-66339-03

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)

Date Mailed July 30, 2007

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, deposit account authority is provided on the accompanying transmittal letter.

Applicants would like to bring to the Examiner's attention co-pending U.S. Patent Application No. 10/489,839.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By

Susan Alpert Siegel, Ph.D.
Registration No. 43,121

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

AUG 02 2007

Attorney Docket Number	4239-66339-03
Application Number	10/523,273
Filing Date	January 31, 2005
First Named Inventor	Klinman
Art Unit	1648
Examiner Name	Michelle S. Horning

U.S. PATENT DOCUMENTS

Copies of U.S. patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		7,094,766	08-2006	Gilchrest et al.
		2006/00740039	04-2006	Klinman et al.
		2003/0087848	05-2003	Bratzler et al.

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Dong et al., "Suppressive Oligodeoxynucleotides Delay the Onset of Glomerulonephritis and Prolong Survival in Lupus-Prone NZB X NZW Mice," <i>Arthritis & Rheumatism</i> 52(2):651-658 (February 2005)
		Dong et al., "Suppressive Oligonucleotides Protect Against Collagen-Induced Arthritis in Mice," <i>Arthritis & Rheumatism</i> 50(5):1686-1689 (May 2004)
		Enokizono et al., "Structure of hnRNP D Complexed with Single-stranded Telomere DNA and Unfolding of the Quadruplex by Heterogeneous Nuclear Ribonucleoprotein D," <i>J. Biological Chemistry</i> 280(19):18862-18870 (2005)
		Iwakura et al., "The Development of Autoimmune Inflammatory Arthropathy in Mice Transgenic for the Human T Cell Leukemia Virus Type-1 env-pX Region is not Dependent on H-2 Haplotypes and Modified by the Expression Levels of Fas Antigen," <i>J. Immunology</i> 161:6592-6598, 1998
		Gursel et al., "Repetitive Elements in Mammalian Telomeres Suppress Bacterial DNA-Induced Immune Activation," <i>J. Immunology</i> 171:1393-1400 (2003)
		Shirota et al., "Suppressive Oligodeoxynucleotides Protect Mice from Lethal Endotoxic Shock," <i>J. Immunology</i> 174:4579-4583 (2005)

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.